 Allakos Inc NASDAQ: ALLK reported data from ENIGMA 2 Phase 3 study of lirentelimab in eosinophilic gastritis EG or eosinophilic duodenitis EoD and KRYPTOS Phase 23 study of lirentelimab in eosinophilic esophagitis EoE. Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints but did not achieve statistical significance on the patient-reported symptomatic co-primary endpoints. 